SCHEMBL4667543

SCHEMBL4667543

CN1CCC(COc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5c(F)cccc5F)cc4)ncn3)cc2F)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.39
KDR P35968 6/20 0.38
IKBKE Q14164 2/20 0.36
TBK1 Q9UHD2 2/20 0.36
AURKA O14965 1/20 0.36
CDK1 P06493 1/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665711 0.95 EGFR (0.38) EGFRKDRIKBKETBK1AURKA
SCHEMBL4667471 0.94 EGFR (0.44) EGFRKDRPDGFRBPDGFRAFLT1
SCHEMBL4665785 0.93 EGFR (0.35) EGFRKDRIKBKETBK1FLT1
SCHEMBL4665829 0.93 EGFR (0.39) EGFRKDRIKBKETBK1MEN1
SCHEMBL4665833 0.92 KDR (0.41) EGFRKDRAURKACDK1PDGFRB
SCHEMBL4667481 0.90 PIK3R1 (0.42) EGFRKDRIKBKETBK1AURKA
SCHEMBL4663781 0.89 EGFR (0.39) EGFRKDRIKBKETBK1FLT1
SCHEMBL4665748 0.89 EGFR (0.42) EGFRKDRIKBKETBK1PDGFRB
SCHEMBL4665787 0.89 ABL1 (0.41) EGFRKDRMETABL1BCR
SCHEMBL4665873 0.87 EGFR (0.44) EGFRKDRABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885KDR 431/4885IKBKE 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.